References
- De Gramont A, Figer A, Seymour M, Omerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–47.
- Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 2000;343:905–14.
- Tournigand C, Louvet C, Quinaux E, Andre T, Lledo G, Flesch M, et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): final results of a phase III study. ASCO Abstracts 4942001.
- Sargent DJ, Niedzwiecki D, O’Connell MJ, Schilsky RL. Recommendation for caution with irinotcan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001;345:144–5.
- Edler D, Glimelius B, Hallstrom M, Jakobsen A, Jonston PG, Magnusson I, et al. Thymidilate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluouracil-based chemotherapy. J Clin Oncol 2002;20: 1721–8.
- Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA, Joensuu H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000;119:921–8.
- Yamamoto H, Itoh F, Nakamura H, Fukushima H, Sasaki S, Perucho M, et al. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res 200;61: 3139–44.
- Su AI, Welsh JB, Sapinosos LM, Kern SG, Dimitrov P, Lapp H, et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001;61:7388–93.
- Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, et al. Multiclass cancer diagnosis using tumor gene expression signatures. PNAS 2001:15149–54.
- Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expresion profiling. Nature 2000; 403:503–11.
- Zhou W, Goodman SNG, Lieto E, Ferraraccio F, Pignatelli C, Purdie CA, et al. Counting alleles to predict recurrence of early stage colorectal cancers. Lancet 2002;359:183–4.
- Petricoin EFI, Ardekani AM, Hit BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572–7.
- Grewe M, Gansauge F, Schmid RM, Adler G, Seufferlein T. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res 1999;59: 3581–7.
- Seufferlein T, Van Lint J, Liptay S, Adler G, Schmid RM. Transforming growth factor alpha activates Ha-ras in human pancreatic cancer cells with Ki-ras mutations. Gastroenterology 1999;116:1441–52.
- Moore MJ, Hamm J, Eisenberg P, Dagenais M, Hagan K, Fields A, et al. A comparison between gemcitabine (GEM) and the matrix metalloproteinase (MMP) inhibitor BAY12–9566 (9566) in patients (PTS) with advanced pancreatic cancer. ASCO Abstracts 2000:930.
- Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001; 19: 3447–55.
- Saltz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that express epidermal growth factor receptor (EGFR). ASCO Abstracts 2001:7.